ConcertAI has inked a deal with Memorial Sloan Kettering Cancer Center to accelerate the development and deployment of clinical AI algorithms.
Under the multiyear strategic agreement, Memorial Sloan Kettering will use AI software-as-a-service (SaaS) technology from ConcertAI's Eureka Life Science AI Platform, powered by TeraRecon. The technology will be used to build, test, and deploy new models for tumor detection, segmentation, classification, and cancer treatment response, ConcertAI said.
The end goal for both organizations is to improve the speed, precision, and generalizability of AI models to allow more patients, trials, and institutions to benefit from the technology, the company added.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
